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Fools rush in where angels fear to tread: damage control surgery for
severe pancreatic trauma
The pancreas is usually considered to be well protected however, it’s anatomical relationships mean that when the
head of the gland is injured there are frequently severe associated injuries to vasculature or important structures
such as the bile duct and duodenum. Major trauma to the pancreatic head therefore, represents a life-threatening
situation for the patient and a complex management issue for the surgeon. In this issue of HPB, Krige and
colleagues from Cape Town, South Africa present a wealth of experience of pancreatic trauma. The article refers
to a cohort of more than 400 pancreatic trauma cases with focus on 19 with the most severe grade 5 injuries. The
mechanism of injury included penetrating trauma from gunshot and stab wounds as well as blunt trauma from
road traffic accidents. Approaches to management were tailored to the individual patient needs. A number of
these cases were associated with major haemorrhage from vena cava or portal vein injuries which required
control prior to dealing with pancreatic injury itself. The concept of damage control surgery originated in South
Africa and this series includes a number of patients who had two or more stage procedures after initial damage
control of the pancreatic injury. This measured approach seems entirely sensible given the potential difficulties of
reconstruction after pancreaticoduodenectomy in an unstable patient. This approach is a good learning point and
must have contributed to the excellent survival rate of 84% in these patients at the extreme end of the pancreatic
trauma scale.
Stephen J Wigmore
Measuring risk factors and outcome in pancreatic surgery
In this issue of HPB, Kunstman et al. analyse a single high volume pancreatic surgeon’s pancreaticoduodenectomy
(PD) practice where drainage was rarely used. The aim of this study was to test the validity of the recently proposed
fistula risk score (FRS). Of the 297 patients who underwent PD, 265 (89%) were included for analysis. No data on
the outcome of those 11% of patients excluded were given. Somatostatin use was not analysed as a variable. Only
7.9% of patients developed a clinical relevant (Grade B/C) pancreatic fistula (CR-POPF). Only 15% of patients
developed a Dindo-Clavien complication > grade 2 and there was no mortality from intra-abdominal complica-
tions. These results are clearly exceptional and are close to a gold standard for pancreatic surgery. The important
findings of the study were that the negative predictive value of a CR-POPF for a low FRS score was 100% but the
positive predictive value for CR-POPF associated with high FRS was low at only 16%, at odds with previous studies
from the proponents of the FRS. This study highlights a number of important issues with regard to the objectivity
of 3 of the 4 proposed variables of the FRS; gland texture, pancreatic duct diameter and blood loss. Gland texture
is a subjective surgical assessment. Was the assessment by Kunstman et al. the same as the initial authors from the
FRS study? Did the initial proponents of the FRS undergo training to standardise assessment and possibly increase
concordance? In the study by Kunstman et al. no mention is given on how the PD diameter was measured. Should
this be measured intra-operatively with callipers or from the preoperative cross sectional imaging – if so, at what
point on the pancreas should it be performed? If done intra-operatively should it be done before or after division
of the duct, measuring the external distended diameter or decompressed internal diameter? Blood loss is notoriously
difficult to assess accurately but the definition in the current study was ‘determined in concert with anaesthesia and
nursing teams’. For this author, the standardising of preoperative risk factors is as significant as the standardisation
of postoperative complications but it is important that these factors are objective and measured by a standard and
reproducible method and this paper highlights the need for ongoing refinement to ensure standardised reporting.
Saxon Connor
Predicting readmissions: sometimes necessary, often preventable
Unplanned readmission following hospitalization is common in every realm of healthcare. Negative connotations
surround readmissions, especially as relate to complications, costs and suspect quality. Readmissions however are
necessary if not inevitable so as to protect quality care. The key is to identify preventable readmissions, and build
quality systems that reliably limit them. Some investigators evaluate large databases to identify improvement targets,
while others evaluate focused clinical cohorts. Spolverato et al. evaluated readmission rates for 338 clinically-
annotated patients who underwent hepatic resection (2008–2012) at Johns Hopkins Hospital, a leading academic
HPB disease centre. They report a high incidence (14.2%; 1/7 patients) of 30-day readmissions and the majority of
these occurred within 7 days of index discharge. Longer, not shorter, initial length of stay (LOS) was clearly
associated with eventual readmission. Patients having prolonged and complicated post-resection LOS were most
likely to be readmitted. The strongest independent predictor of readmission was a major complication (5-fold
higher risk). Similar results have been reported by others across HPB and general surgery, and beg the same
questions. What clinical factors best predict a likely readmission? What patient-specific factors? What should be
changed with in-hospital care? What really are optimal LOS targets? And finally, and perhaps most importantly,
what are winning strategies for heightened post-discharge care that can reliably limit readmission? ‘Mr. W, we
believe you have a 50/50 chance of coming back into hospital. Let’s keep in close touch, and follow these specific
instructions. Working together, we can help you recover safely at home.’
Mark Callery
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